Achieve Life Sciences, Inc. (ACHV)
- Previous Close
2.7300 - Open
2.7500 - Bid 3.0500 x 100
- Ask 3.1400 x 100
- Day's Range
2.6800 - 3.1000 - 52 Week Range
1.8400 - 5.5900 - Volume
557,814 - Avg. Volume
187,579 - Market Cap (intraday)
106.83M - Beta (5Y Monthly) 1.50
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3500 - Earnings Date Aug 11, 2025 - Aug 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.00
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc., which is headquartered in Vancouver, Canada.
www.achievelifesciences.comRecent News: ACHV
View MorePerformance Overview: ACHV
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACHV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACHV
View MoreValuation Measures
Market Cap
106.83M
Enterprise Value
93.55M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
10.39
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-59.02%
Return on Equity (ttm)
-154.55%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-46.16M
Diluted EPS (ttm)
-1.3500
Balance Sheet and Cash Flow
Total Cash (mrq)
23.25M
Total Debt/Equity (mrq)
96.90%
Levered Free Cash Flow (ttm)
-21.11M